Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07606963

Triton 1.5 Robotic System for Diagnostic Colonoscopy

This study is a prospective, single-arm, non-randomized, single-site study, focused on evaluating the safety and efficacy of the Triton 1.5 System in diagnostic and basic therapeutic colonoscopy.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

22 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

HT Centrum Medyczne

Tychy, Silesian Voivodeship, 43-100, Poland

Location contact

Marcin Romanczyk

SUB_INVESTIGATOR

About this study

This study is a prospective clinical investigation designed to evaluate the safety, and efficacy of the Triton 1.5 System in performing diagnostic, screening, surveillance, and basic therapeutic tasks (e.g., polypectomy for lesions ≤ 2cm). Up to 40 subjects will undergo robotic colonoscopy using the Triton 1.5 System with three operating physicians.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥ 22 years
  • Adults indicated for elective screening, surveillance or diagnostic colonoscopy
  • Subject is willing and able to provide written informed consent prior to receiving any non-standard of care protocol specific procedures
  • Subject is willing and able to comply with all protocol required preparation and follow- up visits

Exclusion criteria

  • Any medical or physical condition/limitation that would contraindicate a conventional colonoscopy. This assessment will be made by the investigator.
  • Any active or magnetic implantable medical devices (e.g., pacemakers, defibrillators)
  • Previous failed colonoscopy (except for inadequate bowel preparation)
  • BMI > 45 kg/m2
  • Pregnant participants, women of reproductive potential (pre-menopausal and/or no history of hysterectomy), confirmed by a positive pregnancy test (serum).
  • Surgically altered colonic anatomy
  • History of colorectal cancer, inflammatory bowel disease, polyposis syndrome, hereditary nonpolyposis colorectal cancer (Lynch) syndrome, sclerosing encapsulating peritonitis, active diverticulitis in last 6 months or toxic megacolon
  • Lower gastrointestinal bleeding within 28 days prior to the colonoscopy day
  • Known bleeding tendency such as hemophilia or coagulation factor deficiencies
  • Subject receiving antiplatelet or anticoagulation therapy apart from low-dose aspirin
  • Known colonic stricture
  • Known risk factors for abdominal adhesions such as history of complex abdominal or pelvis surgical procedures, based on investigator assessment
  • Known abdominal wall hernias
  • History of radiotherapy to the abdomen or pelvis
  • History of mesenteric ischemia
  • Known coronary ischemia or cardiovascular stroke within 3 months prior to the colonoscopy procedure
  • Contraindication to the proposed sedation / anesthesia
  • Received any investigational medicine or treatment within 28 days prior to the colonoscopy procedure
  • Received or planning to receive any other endoscopic procedure within 4 weeks prior and 2 weeks after the colonoscopy procedure
  • Participation in any concurrent clinical trial that may impact the results of this study

Intra-Operative Criteria:

  • Inadequate bowel preparation, defined as a Boston Bowel Preparation Scale (BBPS) (Appendix A) score < 2 in any segment.
  • Any intraoperative finding or condition that, in the Investigator's judgment, would make study participation unsafe or not in the subject's best interest (e.g., significant stricture, tight sigmoid colon precluding safe overtube passage).

Treatment and study plan

Diagnostic Test: Diagnostic Colonoscopy

Device

This study will serve to evaluate the safety and efficacy of the Triton 1.5 System for performing diagnostic, screening, surveillance, and basic therapeutic tasks (e.g., polypectomy for lesions ≤2cm).

Primary outcomes

  1. Primary Safety Endpoint - Incident of Major Adverse Events within 48 Hours

    Time frame: 48 Hours

    Absence of Major Adverse Events (MAEs) within 48 hours of the procedure. MAEs are defined as the following: (a) Device-related death within 48 hours, (b) Perforation within 48 hours, (c) Intraprocedural bleeding preventing completion of the procedure, (d) Delayed bleeding within 48 hours accompanied by predefined symptoms and confirmed by a hemoglobin drop of >2 g, as applicable, leading to admission to hospital, prolongation of existing hospital stay, another procedure (requiring sedation/anesthesia).

    Unit of Measure: Number of participants with at least one Major Adverse Event

  2. Primary Efficacy Endpoint - Successful Completion of Colonoscopy During Procedure

    Time frame: During Procedure

    Completion of colonoscopy defined by both: (a) Successful cecal intubation with visualization of the appendiceal orifice, (b) Successful withdrawal with clinically acceptable diagnostic inspection and therapeutic access.

Secondary outcomes

  1. Secondary Safety Endpoint - Mucosal Injury Score During Procedure

    Time frame: During Procedure

    Mucosal Injury graded using a visual assessment of the colonic wall during withdrawal of the procedure using the following scale: (1) Erythema / Bruising, (2) Mucosal break < 5 mm, (3) Mucosal break > 5 mm, (4) Muscle injury (non-full thickness), (5) Full-thickness injury.

    Unit of Measure: Score (1-5), higher scores indicate more severe injury

  2. Secondary Safety Endpoint - Delayed Bleeding Within 14 Days

    Time frame: 14 days post-procedure

    Delayed bleeding within 14 days, defined as: bleeding within 48 hours accompanied by pre-defined symptoms and confirmed by a hemoglobin drop > 2 g, leading to admission to hospital, prolongation of existing hospital stay, another procedure (requiring sedation/anesthesia).

  3. Secondary Safety Endpoint - Delayed Perforations Within 14 Days

    Time frame: 14 days post-procedure

    Delayed perforations within 14 days, defined as: perforations occurring within 14 days post-procedure.

  4. Secondary Efficacy Endpoint - Time to Cecum During Procedure

    Time frame: During Procedure

    Interval from nested-system insertion at the anal verge to first visualization of the appendiceal orifice. Pauses for ancillary or therapeutic tasks (e.g., biopsy, polypectomy ≤ 2 cm, repositioning, prolonged washing) are recorded and subtracted to isolate insertion performance. For polypectomy pauses, time is measured from first polyp visualization to confirmation of retrieval in the specimen trap.

    Unit of Measure: Minutes or seconds

  5. Secondary Efficacy Endpoint - Need for Repositioning During Procedure

    Time frame: During Procedure

    Number of times a participant was repositioned during the procedure. Unit of Measure: Number of repositioning events

  6. Secondary Efficacy Endpoint - Polypectomy Success During Procedure

    Time frame: During Procedure

    Clinically acceptable polypectomy performed with cold forceps, cold snare, or hot snare leaving no visible residual polyp. Polyps > 2 cm or lesions too complex for diagnostic colonoscopy are excluded and deferred for later advanced therapy.

  7. Secondary Efficacy Endpoint - NASA Task Load Index (NASA-TLX) Post-Procedure

    Time frame: Immediately after Procedure

    Physician's subjective workload assessment using the NASA Task Load Index (NASA-TLX), a validated tool consisting of six subscales: Mental Demand, Physical Demand, Temporal Demand, Performance, Effort, and Frustration. Each subscale is scored from 0 to 100 in increments of 5. Higher scores indicate greater perceived workload. Unit of Measure: Composite score (0-600)

  8. Secondary Efficacy Endpoint - Adenoma Detection Rate During Procedure

    Time frame: During Procedure

    Percentage of subjects with ≥ 1 histologically confirmed adenoma or carcinoma Unit of Measure: Percentage of participants

Study contacts

Contact information is provided by the study sponsor or research team.

Hayley Holm

CONTACT

[email protected]

(650) 922-5512

Min-Sun Son

CONTACT

[email protected]

(650) 714-1803

Sponsors and collaborators

Lead sponsor

Neptune Medical

Industry

Collaborators

  • H-T. Centrum Medyczne Sp. z o.o. sp. k
  • KCRI

Registry information

Official study title

Initial Clinical Experience With the Triton 1.5 Robotic System for Diagnostic Colonoscopy

Acronym: CARE II

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
May 26, 2026
Registry last updated
May 26, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.